GeoVax Labs, Inc. (NASDAQ: GOVX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $8.00 price target on the stock.
GeoVax Partners with Allucent to Conduct Phase 2b Clinical Study of Next-Generation COVID-19 Vaccine Candidate with Funding from BARDA [Yahoo! Finance]
GeoVax Labs, Inc. (NASDAQ: GOVX) had its price target raised by analysts at HC Wainwright from $8.00 to $120.00. They now have a "buy" rating on the stock.
GeoVax Receives BARDA Project NextGen Award to Conduct Phase 2b Clinical Study Evaluating the Company's Next-Generation COVID-19 Vaccine Candidate, GEO-CM04S1 [Yahoo! Finance]
GeoVax to Present at BIO International Convention 2024 [Yahoo! Finance]